PureTech Health plc is a biopharmaceutical company that develops medicines designed to address complex diseases, with a focus on disorders involving the immune system, the brain, and the body’s lymphatic system. The company uses its proprietary therapeutic platforms to discover and advance drug candidates, either independently or through subsidiaries and strategic partnerships.
PureTech’s development portfolio has included treatments for neurological, immunological, inflammatory, and fibrotic conditions. Its most notable program originated through Karuna Therapeutics, a PureTech-founded company that developed KarXT, a combination of xanomeline and trospium, for schizophrenia and Alzheimer’s disease-related psychosis. PureTech also advances its own pipeline, including candidates intended to modulate lymphatic and neuroimmune pathways, and may retain economic interests in products developed by or partnered with its subsidiaries.
Founded in 2015, PureTech is headquartered in Boston, Massachusetts, with operations and activities spanning the United States, the United Kingdom, and other international markets through global research, clinical-development, and partnering programs. The company was founded and is led by Daphne Zohar, who serves as chief executive officer. Its medicines are generally developed for worldwide use through regulatory approvals and collaborations with pharmaceutical companies.
AI Generated. May Contain Errors.
Free PRTC Stock Alerts